Lupin, Sandoz Tie Up to Market Ranibizumab in Multiple Global Markets

Lupin Ltd. has partnered with Switzerland-based Sandoz Group AG to market and commercialise Ranibizumab across the EU (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia. Lupin will handle manufacturing, regulatory submissions, and approvals, while Sandoz will get exclusive marketing rights in most markets and semi-exclusive rights in France, Australia, Vietnam, and Malaysia.

Under a separate deal, Sandoz will secure sole commercialisation rights for Lupin’s biosimilar Ranibizumab in Canada, with Lupin managing manufacturing and regulatory filings. Ranibizumab is used to treat eye conditions linked to abnormal blood vessel growth.